Cannabis-based medicines improved quality of life for autism patients in UK registry
Patients with autism spectrum disorder treated with cannabis-based medicines showed significant improvements in anxiety, sleep, and overall quality of life over six months in a UK medical registry.
Quick Facts
What This Study Found
Among 74 ASD patients (mean age 32.7), significant improvements were seen in general quality of life (EQ-5D-5L), sleep quality (SQS), and anxiety (GAD-7) at 1 and 3 months. Quality of life and sleep improvements were sustained at 6 months. Most adverse events were mild (78.4%) or moderate (109.5%), rather than severe (55.4%).
Key Numbers
74 ASD patients, mean age 32.7 years. Significant improvements in EQ-5D-5L, SQS, and GAD-7 at 1 and 3 months. EQ-5D-5L and SQS improvements sustained at 6 months.
How They Did This
Observational case series from the UK Medical Cannabis Registry analyzing patients treated with cannabis-based medicinal products for ASD-related symptoms for at least 1 month. Outcomes measured using validated instruments (GAD-7, SQS, EQ-5D-5L) at baseline, 1, 3, and 6 months.
Why This Research Matters
Few effective treatments exist for the anxiety, sleep problems, and quality-of-life challenges that commonly accompany autism. This registry data provides early real-world evidence on cannabis-based medicines for these symptoms.
The Bigger Picture
Registry data from clinical practice provides real-world evidence that complements the limited controlled trial data on cannabis for autism, though it cannot establish causation.
What This Study Doesn't Tell Us
No control group. Subject to attrition bias. Registry data cannot determine whether improvements were from cannabis medicines, placebo effect, or other factors. Relatively small sample size.
Questions This Raises
- ?Would these improvements hold up in a randomized controlled trial?
- ?Which cannabis formulations and doses are optimal for ASD-related symptoms?
Trust & Context
- Key Stat:
- Significant improvements in quality of life and sleep sustained at 6 months
- Evidence Grade:
- Observational case series without controls. Promising but subject to multiple biases including placebo effect and attrition.
- Study Age:
- Published in 2022.
- Original Title:
- Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry.
- Published In:
- Therapeutic advances in psychopharmacology, 12, 20451253221116240 (2022)
- Authors:
- Erridge, Simon(22), Kerr-Gaffney, Jess, Holvey, Carl(10), Coomber, Ross, Barros, Daniela A Riano, Bhoskar, Urmila, Mwimba, Gracia, Praveen, Kavita, Symeon, Chris, Sachdeva-Mohan, Simmi, Sodergren, Mikael H, Rucker, James J
- Database ID:
- RTHC-03828
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What symptoms improved?
Anxiety (measured by GAD-7), sleep quality (measured by SQS), and overall quality of life (measured by EQ-5D-5L) all showed significant improvement, with quality of life and sleep gains lasting through 6 months.
Were there side effects?
Yes, adverse events were reported, but the majority were classified as mild or moderate. Severe adverse events occurred less frequently.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03828APA
Erridge, Simon; Kerr-Gaffney, Jess; Holvey, Carl; Coomber, Ross; Barros, Daniela A Riano; Bhoskar, Urmila; Mwimba, Gracia; Praveen, Kavita; Symeon, Chris; Sachdeva-Mohan, Simmi; Sodergren, Mikael H; Rucker, James J. (2022). Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry.. Therapeutic advances in psychopharmacology, 12, 20451253221116240. https://doi.org/10.1177/20451253221116240
MLA
Erridge, Simon, et al. "Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry.." Therapeutic advances in psychopharmacology, 2022. https://doi.org/10.1177/20451253221116240
RethinkTHC
RethinkTHC Research Database. "Clinical outcome analysis of patients with autism spectrum d..." RTHC-03828. Retrieved from https://rethinkthc.com/research/erridge-2022-clinical-outcome-analysis-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.